Porcine antibody profiles of 33 Mycoplasma hyopneumoniae fusion proteins from M. hyopneumoniae natural infection but not vaccination.
ELISA
GST fusion protein
convalescent sera
hyperimmune sera
immunodominant protein
Journal
Veterinary medicine and science
ISSN: 2053-1095
Titre abrégé: Vet Med Sci
Pays: England
ID NLM: 101678837
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
pubmed:
16
12
2022
medline:
25
1
2023
entrez:
15
12
2022
Statut:
ppublish
Résumé
Mycoplasma hyopneumoniae, the primary pathogen responsible for porcine enzootic pneumonia, reduces average daily weight gain and causes substantial economic losses to the pig industry worldwide. Vaccination is the most common strategy to control this disease but offers partial protection. Therefore, developing next-generation vaccines by screening protective antigens is crucial. The aim of this study was to evaluate the antibody response to 33 recombinant proteins in pigs naturally infected with M. hyopneumoniae. The genes encoding 33 (hypothetical) membrane proteins or secretory proteins were ligated into pGEX-6P-1, pGEX-6P-2, pGEX-5X-3 or pGEX-4T-3 vectors and transformed into Escherichia coli BL21(DE3) or E. coli XL-1 Blue to construct recombinant bacteria and to express the recombinant proteins. The recombinant bacteria expressing the target proteins reacted with porcine convalescent sera and negative sera to screen immunodominant proteins by ELISA. Then, recombinant bacteria expressing immunodominant proteins were used to identify the discriminating immunodominant proteins that were recognised by convalescent sera nut not hyperimmune sera. All recombinant bacteria could express the target recombinant proteins in soluble form. Twenty-one proteins were shown to present immunodominant antigens, and four proteins were not recognised by convalescent sera. Moreover, six proteins were considered discriminating and reacted with convalescent sera but not with hyperimmune sera. The identified immunodominant proteins were antigenic and expressed during bacterial infection, suggesting that these proteins, especially those capable of discriminating between sera, can be used to identify protective antigens with the view to develop more effective vaccines against M. hyopneumoniae infection.
Sections du résumé
BACKGROUND
Mycoplasma hyopneumoniae, the primary pathogen responsible for porcine enzootic pneumonia, reduces average daily weight gain and causes substantial economic losses to the pig industry worldwide. Vaccination is the most common strategy to control this disease but offers partial protection. Therefore, developing next-generation vaccines by screening protective antigens is crucial.
OBJECTIVES
The aim of this study was to evaluate the antibody response to 33 recombinant proteins in pigs naturally infected with M. hyopneumoniae.
METHODS
The genes encoding 33 (hypothetical) membrane proteins or secretory proteins were ligated into pGEX-6P-1, pGEX-6P-2, pGEX-5X-3 or pGEX-4T-3 vectors and transformed into Escherichia coli BL21(DE3) or E. coli XL-1 Blue to construct recombinant bacteria and to express the recombinant proteins. The recombinant bacteria expressing the target proteins reacted with porcine convalescent sera and negative sera to screen immunodominant proteins by ELISA. Then, recombinant bacteria expressing immunodominant proteins were used to identify the discriminating immunodominant proteins that were recognised by convalescent sera nut not hyperimmune sera.
RESULTS
All recombinant bacteria could express the target recombinant proteins in soluble form. Twenty-one proteins were shown to present immunodominant antigens, and four proteins were not recognised by convalescent sera. Moreover, six proteins were considered discriminating and reacted with convalescent sera but not with hyperimmune sera.
CONCLUSIONS
The identified immunodominant proteins were antigenic and expressed during bacterial infection, suggesting that these proteins, especially those capable of discriminating between sera, can be used to identify protective antigens with the view to develop more effective vaccines against M. hyopneumoniae infection.
Identifiants
pubmed: 36520664
doi: 10.1002/vms3.1053
pmc: PMC9857121
doi:
Substances chimiques
Antigens, Bacterial
0
Recombinant Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
203-216Informations de copyright
© 2022 The Authors. Veterinary Medicine and Science published by John Wiley & Sons Ltd.
Références
Vaccine. 2003 Jan 17;21(5-6):532-7
pubmed: 12531653
Open Biol. 2016 Feb;6(2):150210
pubmed: 26865024
Vet J. 2011 Apr;188(1):48-52
pubmed: 20605734
J Bacteriol. 2011 Feb;193(4):1016-7
pubmed: 21148737
DNA Cell Biol. 2019 Sep;38(9):922-932
pubmed: 31329463
Infect Immun. 2003 Mar;71(3):1155-60
pubmed: 12595427
BMC Genomics. 2013 Mar 14;14:175
pubmed: 23497205
Microb Pathog. 2001 Feb;30(2):101-10
pubmed: 11162190
Vet Microbiol. 2010 Jul 14;143(2-4):410-6
pubmed: 20053508
Protein Sci. 2003 Aug;12(8):1652-62
pubmed: 12876315
J Proteomics. 2017 Feb 10;154:69-77
pubmed: 28003119
J Bacteriol. 2004 Nov;186(21):7123-33
pubmed: 15489423
J Bacteriol. 2005 Aug;187(16):5568-77
pubmed: 16077101
Protein Expr Purif. 2005 Mar;40(1):1-22
pubmed: 15721767
Vet Microbiol. 2008 Jan 25;126(4):297-309
pubmed: 17964089
Vet J. 2016 Jun;212:1-6
pubmed: 27256017
Am J Vet Res. 1994 Dec;55(12):1697-702
pubmed: 7887513
BMC Vet Res. 2019 Sep 12;15(1):327
pubmed: 31511007
Vaccine. 2011 Feb 17;29(9):1731-5
pubmed: 21237277
Vet Microbiol. 2010 May 19;142(3-4):293-302
pubmed: 19913364
Vet Med Sci. 2023 Jan;9(1):203-216
pubmed: 36520664
BMC Bioinformatics. 2005 Jul 02;6:167
pubmed: 15992409
Res Vet Sci. 1997 Nov-Dec;63(3):215-7
pubmed: 9491446
Sheng Wu Gong Cheng Xue Bao. 2018 Jan 25;34(1):44-53
pubmed: 29380570
J Mol Biol. 2004 May 14;338(5):1027-36
pubmed: 15111065
BMC Vet Res. 2017 Aug 29;13(1):274
pubmed: 28851359
Infect Immun. 2008 Feb;76(2):658-63
pubmed: 18070898
Nat Biotechnol. 2019 Apr;37(4):420-423
pubmed: 30778233
BMC Genomics. 2014 Jul 08;15:576
pubmed: 25005615
Vaccine. 2006 Nov 30;24(49-50):7081-6
pubmed: 16934376
Vaccine. 2010 Jul 5;28(30):4802-9
pubmed: 20472025
Comp Immunol Microbiol Infect Dis. 2012 Mar;35(2):209-16
pubmed: 22304900
J Mol Biol. 2001 Jan 19;305(3):567-80
pubmed: 11152613
Transbound Emerg Dis. 2018 May;65 Suppl 1:110-124
pubmed: 28834294
Vet Microbiol. 2019 Mar;230:195-201
pubmed: 30827388
PLoS One. 2014 Nov 11;9(11):e112596
pubmed: 25386928